Sarbajit Mukherjee, Chief of GI Medical Oncology at Miami Cancer Institute and Co-Chair of GI Clinical Trial Working Group at Hoosier Cancer Research Network, shared a post on LinkedIn:
“As cancer immunotherapy moves beyond PD-1/PD-L1 and CTLA-4, we must recognize that each new immune target may have its own toxicity fingerprint.
Kudos to Yu Fujiwara on publishing this important systematic review and meta-analysis in JNCI Cancer Spectrum.
Across 27 trials and 3,946 patients, the key findings were:
LAG-3–directed therapy was associated with increased adrenal insufficiency, and arthralgia.
- TIGIT blockade was associated with increased rash, without a significant increase in severe adverse events.
- Pooled analyses identified additional toxicity signals: pneumonitis and hepatitis with TIM-3, rash with CD40 agonists, and diarrhea with OX40 agonists.
The key message for clinicians and drug developers: emerging checkpoints should not be assumed to share the safety profile of established immunotherapies. Target-specific monitoring must become part of trial design and clinical implementation.
Congratulations, Fuji, and to our entire collaborative team!”
Title: Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis
Authors: Yu Fujiwara, Yui Okamura, Mrinalini Ramesh, Yasmin Fakhari Tehrani, Riona Aburaki, Toshiaki Takahashi, Manmeet S Ahluwalia, Sarbajit Mukherjee
Read The Full Article
Other articles about immunotherapy on OncoDaily.